Vulgarin
Vulgarin is an orally active, naturally occurring eudesmane sesquiterpene with multiple biological activities including anti-inflammatory and antioxidant properties. Vulgarin targets and inhibits HMGB1, NF-κB and iNOS, while regulating key genes involved in hepatic gluconeogenesis; it also blocks inflammatory signaling pathways and inhibits the production and release of pro-inflammatory cytokines such as TNF-α and IL-1β. Vulgarin effectively alleviates pancreatic oxidative stress by reducing lipid peroxidation levels and restoring antioxidant enzyme activity. Vulgarin reverses abnormally elevated serum pancreatic enzyme levels, preserves the integrity of pancreatic acinar cells, and reduces pancreatic edema, hemorrhage and inflammatory infiltration. Vulgarin remodels the function of pancreatic endocrine cells, restores insulin content in β cells, and downregulates glucagon levels in α cells and somatostatin levels in δ cells. Vulgarin can be used in studies related to pancreatic injury and diabetes.
For research use only. We do not sell to patients.
- CAS No.: 3162-56-9
- Formula: C15H20O4
- Molecular Weight:264.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
iNOS |
IL-1β |
TNF-α |
NF-κB |
In Vivo
Vulgarin (VGN) (10-20 mg/kg; p.o.; once daily; for 8 weeks) exhibits dose-dependent antidiabetic activity in Streptozotocin (HY-13753)-induced diabetic rats, with the combination of the 20 mg/kg dose and Glibenclamide (HY-15206) yielding the optimal efficacy[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (adult male, 180-200 g, pancreatic ischemia-reperfusion injury induced by occluding the splenic artery for 60 minutes followed by reperfusion)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:p.o.; daily for 2 days, plus a single dose 24 hours post-reperfusion
-
Result:Reduced serum amylase, lipase and TAP in a dose-dependent manner, with respective declines of 40.7%, 38.7%, 37.5% at 10 mg/kg and 70.8%, 61.7%, 65.6% at 20 mg/kg relative to ischemia-reperfusion model rats.
Alleviated pancreatic MDA level while elevating GPx and MPO activities; the 10 mg/kg dose produced 35.3% MDA reduction, 2.3-fold GPx elevation and 2.9-fold MPO elevation, whereas the 20 mg/kg dose led to 64.7% MDA reduction, 4.0-fold GPx elevation and 5.3-fold MPO elevation.
Suppressed pancreatic TNF-α, IL-1β and NF-κB contents dose-dependently.
Inhibited pancreatic HMGB1 gene expression at both tested dosages.
Mitigated pancreatic necrosis and inflammatory infiltration at 10 mg/kg, relieved pancreatic edema at 20 mg/kg, and ameliorated hepatic sinusoidal dilatation together with hepatic inflammatory infiltration under two concentrations.
Decreased pancreatic iNOS expression at both 10 mg/kg and 20 mg/kg doses.
-
Animal Model:Wistar rats (male, 180-200 g, streptozotocin-induced diabetic)[2]
-
Dosage:10 mg/kg; 20 mg/kg; 10 mg/kg plus glibenclamide 5 mg/kg; 20 mg/kg plus glibenclamide 5 mg/kg
-
Administration:p.o.; daily; 8 weeks
-
Result:Produced dose-dependent improvements in blood glucose, insulin, glycated hemoglobin, hemoglobin and serum lipid profiles after 8-week 10 mg/kg and 20 mg/kg vulgarin monotherapy; combined treatment of vulgarin with glibenclamide further strengthened these metabolic regulatory effects, with 20 mg/kg vulgarin combined with glibenclamide restoring most indicators close to normal values.
Raised pancreatic SOD, GPx and CAT activities while lowering pancreatic MDA content in a dose-dependent manner under vulgarin single administration, and the combination regimen achieved stronger antioxidant capacity and lower MDA accumulation after 8 weeks of treatment.
Suppressed hepatic PEPCK and G6Pase mRNA expression against diabetic group in both single-drug groups; the combined high-dose treatment completely normalized the two gluconeogenic gene transcripts and nearly recovered pancreatic islet structure as well as β-cell quantity.
Chemical Information
-
CAS No. 3162-56-9
-
Molecular Weight 264.32
-
Formula C15H20O4
-
SMILES
C[C@]12[C@@]([C@](O)(C=CC2=O)C)([H])[C@]3([H])[C@@]([C@@H](C(O3)=O)C)([H])CC1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[1]. Althurwi HN, et al. Effect of Vulgarin and Epivulgarin on Ischemia-Reperfusion-Induced Pancreatic Injury in Rats: A Biochemical, Molecular, and Histopathological Evaluation. Journal of experimental pharmacology. 2026;18:563840. [Content Brief]
[2]. Althurwi HN, et al. Vulgarin, a Sesquiterpene Lactone from , Improves the Antidiabetic Effectiveness of Glibenclamide in Streptozotocin-Induced Diabetic Rats via Modulation of PEPCK and G6Pase Genes Expression. International journal of molecular sciences. 2022 Dec 13;23(24):15856. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)